Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ): HQ2216 obtains clinical trial approval.
Bai Cheng Pharmaceutical (301096.SZ) announcement, the company's wholly-owned subsidiary Bai Cheng Pharmaceutical (Zhuhai Hengqin) Co., Ltd....
Hangzhou Bio-Sincerity Pharma-Tech (301096.SZ) announced that its wholly-owned subsidiary, Hangzhou Bio-Sincerity Pharma-Tech (Zhuhai Hengqin) Co., Ltd., recently received a clinical trial approval notification from the National Medical Products Administration (NMPA). The company's independently developed drug HQ2216 will undergo clinical trial research for the prevention of stress-induced ulcer bleeding in critically ill patients.
Related Articles
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
Industrial: Hong Kong stock market sentiment index has reached the bottom area.
"The 'Chinese Choice' for Global SiC Core Customers: Why TIANYU SEMI (02658)?"
Guosen: RWA welcomes the era of strict supervision.
RECOMMEND
Nine Companies With Market Value Over RMB 100 Billion Awaiting, Hong Kong IPO Boom Continues Into 2026
07/02/2026
Hong Kong IPO Cornerstone Investments Surge: HKD 18.52 Billion In First Month, Up More Than 13 Times Year‑On‑Year
07/02/2026
Over 400 Companies Lined Up For Hong Kong IPOs; HKEX Says Market Can Absorb
07/02/2026
